Point72 Asset Management
TGTX icon

Point72 Asset Management’s TG Therapeutics TGTX Stock Holding History

Point72 Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100,000
Closed -$2.34M – 2447
2024
Q3 		$2.34M Buy
+100,000
New +$2.18M 0.01% 1137

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Point72 Asset Management's TGTX Position: Q1 2026 in Review

Point72 Asset Management sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 231,358 shares — an estimated $6.9M sold.

Point72 Asset Management first reported a position in TGTX in Q1 2018 and held it in 12 quarters. The position peaked at $25.8M in Q2 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Point72 Asset Management reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 231,358 TG Therapeutics shares in Q1 2026, an estimated $6.9M.
  • Point72 Asset Management first reported a position in TG Therapeutics in Q1 2018 and held it in 12 quarters.
  • Point72 Asset Management's TG Therapeutics position peaked at $25.8M in Q2 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.